Orbimed Advisors LLC Sells 2,982,378 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL)

Orbimed Advisors LLC reduced its holdings in Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) by 49.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,103,623 shares of the company's stock after selling 2,982,378 shares during the period. Orbimed Advisors LLC owned about 1.06% of Lyell Immunopharma worth $1,986,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of LYEL. Decheng Capital LLC purchased a new stake in Lyell Immunopharma in the 4th quarter worth about $7,622,000. Foresite Capital Management V LLC purchased a new stake in shares of Lyell Immunopharma during the 4th quarter worth about $5,205,000. Renaissance Technologies LLC raised its stake in shares of Lyell Immunopharma by 716.7% during the 4th quarter. Renaissance Technologies LLC now owns 1,612,146 shares of the company's stock worth $1,032,000 after purchasing an additional 1,414,746 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Lyell Immunopharma during the 4th quarter worth about $887,000. Finally, Almitas Capital LLC purchased a new stake in shares of Lyell Immunopharma during the 4th quarter worth about $672,000. 66.05% of the stock is owned by hedge funds and other institutional investors.

Lyell Immunopharma Stock Up 3.3%

Shares of LYEL traded up $0.01 during midday trading on Friday, reaching $0.42. 790,681 shares of the stock were exchanged, compared to its average volume of 1,041,189. Lyell Immunopharma, Inc. has a 12-month low of $0.39 and a 12-month high of $2.85. The firm has a 50 day simple moving average of $0.47 and a 200-day simple moving average of $0.66. The company has a market cap of $122.57 million, a price-to-earnings ratio of -0.53 and a beta of -0.25.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.01. The business had revenue of $0.01 million for the quarter. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. Research analysts expect that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current fiscal year.

Insider Activity

In other Lyell Immunopharma news, CEO Lynn Seely bought 175,000 shares of the stock in a transaction on Friday, March 14th. The shares were purchased at an average price of $0.61 per share, with a total value of $106,750.00. Following the acquisition, the chief executive officer now directly owns 712,500 shares of the company's stock, valued at $434,625. This represents a 32.56% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Sumant Ramachandra bought 200,000 shares of the stock in a transaction on Friday, March 21st. The stock was acquired at an average cost of $0.58 per share, for a total transaction of $116,000.00. Following the acquisition, the director now directly owns 200,000 shares in the company, valued at approximately $116,000. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 768,640 shares of company stock valued at $449,508. Insiders own 25.10% of the company's stock.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a "neutral" rating and set a $1.00 price target on shares of Lyell Immunopharma in a research note on Wednesday, April 16th.

Lyell Immunopharma Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.